abstract: Seventy-five embryos were collected 6 days after ovulation. Sixty embryos were frozen in straws using @entity0 as the cryoprotectant in an automatic freezer. In Experiment 1 the freezing and thawing media were supplemented with 1.3 g/l @entity2 ; in Experiment 2 the supplement was 5% FCS. The embryos were thawed for 30 s at +37 degrees C in a waterbath. In Experiment 1 @entity0 was removed from 10 embryos in 6 steps. In 10 other embryos, @entity0 and @entity1 were both removed from the medium in 6 steps. After @entity0 and @entity1 removal, the embryos were stained with @entity3 ( @entity3 ) to count the percentage of dead cells. Fluorescent rate (FR) was defined as a ratio of fluorescent area versus total area. Mean (+/- s.d.) FR in this experiment was significantly lower (P<0.01) in embryos thawed with @entity1 (0.28 +/- 0.13) than in embryos thawed with @entity0 alone (0.53 +/- 0.25). In Experiment 2, 40 embryos were frozen and @entity0 , with or without @entity1 , was removed after thawing as for Experiment 1. Ten embryos in both groups were stained with @entity3 . All the frozen-thawed embryos were transferred nonsurgically to recipient mares. Fourteen fresh embryos were transferred as controls, 7 of which were stained with @entity3 before transfer. There was no difference in pregnancy rates between @entity3 -stained versus nonstained embryos, indicating that the staining process had no negative effects on embryonic survival. Insufficient embryos were transferred to be able to demonstrate any difference in pregnancy rates between embryos thawed with or without @entity1 in the medium.

title: The effect of XXXX in the thawing solution on the morphology and mobility of frozen equine embryos.

answer: @entity1


abstract: Loss of chromosomes is a recurrent event in @entity0 . Chromosome-10 losses occur with @entity0 progression and characterize advanced @entity1 . This chromosome carries many genes involved in @entity2 metabolism. Hexokinase (HK) gene is located on chromosome-10. Hexokinase enzymatic activity is decreased in @entity3 . Hexokinase enables @entity2 entry into glycolysis and is critical for these highly glycolytic @entity0 . These enzyme is either free in the cytosol or bound to the mitochondrial outer membrane. Disturbance of HK binding to mitochondria by @entity6 led to inhibition of cells and xenografted- @entity1 growth. Hexokinase bind to a mitochondrial porin which involved peripheral @entity4 receptors. Inhibition of HK and peripheral @entity4 receptors by @entity6 and @entity5 led to synergistic antitumoral activity in xenografted @entity1 . Co-inhibition of these two receptors will lead to a decrease in glycolysis, often elevated in these @entity0 , without modifying energetic metabolism of normal cells.

title: [Targeting the gene of XXXX metabolism for the treatment of advanced @entity1 ].

answer: @entity2


abstract: Loss of chromosomes is a recurrent event in @entity0 . Chromosome-10 losses occur with @entity0 progression and characterize advanced @entity1 . This chromosome carries many genes involved in @entity2 metabolism. Hexokinase (HK) gene is located on chromosome-10. Hexokinase enzymatic activity is decreased in @entity3 . Hexokinase enables @entity2 entry into glycolysis and is critical for these highly glycolytic @entity0 . These enzyme is either free in the cytosol or bound to the mitochondrial outer membrane. Disturbance of HK binding to mitochondria by @entity6 led to inhibition of cells and xenografted- @entity1 growth. Hexokinase bind to a mitochondrial porin which involved peripheral @entity4 receptors. Inhibition of HK and peripheral @entity4 receptors by @entity6 and @entity5 led to synergistic antitumoral activity in xenografted @entity1 . Co-inhibition of these two receptors will lead to a decrease in glycolysis, often elevated in these @entity0 , without modifying energetic metabolism of normal cells.

title: [Targeting the gene of @entity2 metabolism for the treatment of advanced XXXX ].

answer: @entity1


abstract: BACKGROUND: We hypothesize that after successful closed reduction of pediatric greenstick fractures of the forearm, there is a low rate of lost reduction requiring intervention. By reducing the frequency of clinical and radiographic follow-up, we can reduce costs and radiation exposure. METHODS: A retrospective analysis was performed on @entity0 aged 2 to 16 years treated with closed reduction and cast immobilization for greenstick fractures of the forearm at our institution between 2003 and 2013. The primary endpoint was a healed @entity1 with acceptable alignment at the final radiographic evaluation. Time-derived activity-based costing was used for cost analysis. We estimated radiation exposure in consultation with our hospital's radiation safety office. RESULTS: One hundred and nine @entity0 with an average age of 6.9 years (range, 2 to 15 y) met the inclusion criteria. The initial maximal @entity1 angulation of the affected radius and/or ulna averaged 19.3 (SD=  8.7) degrees (range, 2 to 55 degrees). @entity0 were followed for an average of 60 days (range, 19 to 635 d). On average, @entity0 received 3.6 follow-up clinical visits and 3.5 sets of radiographs following immediate emergency department care. Ninety-four percent of @entity0 met criteria for acceptable radiographic alignment. Only 1 @entity0 (0.9%; 95% confidence interval, 0.2%-5.0%) underwent rereduction, as determined by the treating physician. If clinical follow-up were limited to 2 visits and 3 sets of radiographs total, there would be a 14.3% reduction in total cost of @entity1 care and a 41% reduction in radiation exposure. CONCLUSIONS: This retrospective study suggests that pediatric greenstick fractures of the forearm rarely require intervention after initial closed reduction. We propose that 2 clinical follow-up visits and 3 sets of radiographs would reduce overall care costs and radiation exposure without compromising clinical results. LEVEL OF EVIDENCE: Level IV-economic and decision analyses.

title: Reducing Cost and Radiation Exposure During the Treatment of XXXX of the Forearm.

answer: @entity1


abstract: @entity9 ( @entity9 ), usually confined to the nasopharynx, @entity3 , and larynx, occasionally can progress to extensive @entity2 . Most cases of @entity11 are cytologically benign and do not undergo malignant transformation; however, @entity5 ( @entity5 ) can arise in @entity9 in the absence of known risk factors such as radiation and smoking. In this study, the authors investigated molecular genetic alterations occurring in a case of metastasizing @entity5 that arose in long-standing @entity8 . Genomic DNA from @entity10 , @entity12 , @entity5 of the lung, and a lymph node @entity0 was extracted. The physical state of the @entity7 type 11 (HPV-11) DNA was investigated by two-dimensional gel electrophoresis. Molecular genetic alterations of the host genome were studied by direct sequencing of polymerase chain reaction-amplified gene fragments and restriction fragment length polymorphism (RFLP) analysis. Episomal and integrated forms of HPV-11 sequences were detected in histologically benign @entity1 , but only the integrated form of the viral DNA could be found in malignant tissue samples. Molecular genetic studies revealed that an allelic loss of the interferon-beta gene (IFNbeta-1) and an endogenous type of mutation of the @entity4 antioncogene were found only in the @entity1 . Mutations were not observed in the ras, neu, or multiple @entity1 suppressor ( @entity6 / @entity6 ) genes in any specimens. The authors' data indicated that the @entity4 genetic mutation was associated with integration of HPV-11 in histologically @entity1 . This association may promote a progressive genetic instability that can lead to the development and clonal expansion of @entity1 in @entity9 .

title: Malignant transformation of recurrent @entity9 associated with integrated @entity7 type 11 DNA and mutation of XXXX .

answer: @entity4


abstract: @entity9 ( @entity9 ), usually confined to the nasopharynx, @entity3 , and larynx, occasionally can progress to extensive @entity2 . Most cases of @entity11 are cytologically benign and do not undergo malignant transformation; however, @entity5 ( @entity5 ) can arise in @entity9 in the absence of known risk factors such as radiation and smoking. In this study, the authors investigated molecular genetic alterations occurring in a case of metastasizing @entity5 that arose in long-standing @entity8 . Genomic DNA from @entity10 , @entity12 , @entity5 of the lung, and a lymph node @entity0 was extracted. The physical state of the @entity7 type 11 (HPV-11) DNA was investigated by two-dimensional gel electrophoresis. Molecular genetic alterations of the host genome were studied by direct sequencing of polymerase chain reaction-amplified gene fragments and restriction fragment length polymorphism (RFLP) analysis. Episomal and integrated forms of HPV-11 sequences were detected in histologically benign @entity1 , but only the integrated form of the viral DNA could be found in malignant tissue samples. Molecular genetic studies revealed that an allelic loss of the interferon-beta gene (IFNbeta-1) and an endogenous type of mutation of the @entity4 antioncogene were found only in the @entity1 . Mutations were not observed in the ras, neu, or multiple @entity1 suppressor ( @entity6 / @entity6 ) genes in any specimens. The authors' data indicated that the @entity4 genetic mutation was associated with integration of HPV-11 in histologically @entity1 . This association may promote a progressive genetic instability that can lead to the development and clonal expansion of @entity1 in @entity9 .

title: Malignant transformation of recurrent @entity9 associated with integrated XXXX type 11 DNA and mutation of @entity4 .

answer: @entity7


abstract: @entity9 ( @entity9 ), usually confined to the nasopharynx, @entity3 , and larynx, occasionally can progress to extensive @entity2 . Most cases of @entity11 are cytologically benign and do not undergo malignant transformation; however, @entity5 ( @entity5 ) can arise in @entity9 in the absence of known risk factors such as radiation and smoking. In this study, the authors investigated molecular genetic alterations occurring in a case of metastasizing @entity5 that arose in long-standing @entity8 . Genomic DNA from @entity10 , @entity12 , @entity5 of the lung, and a lymph node @entity0 was extracted. The physical state of the @entity7 type 11 (HPV-11) DNA was investigated by two-dimensional gel electrophoresis. Molecular genetic alterations of the host genome were studied by direct sequencing of polymerase chain reaction-amplified gene fragments and restriction fragment length polymorphism (RFLP) analysis. Episomal and integrated forms of HPV-11 sequences were detected in histologically benign @entity1 , but only the integrated form of the viral DNA could be found in malignant tissue samples. Molecular genetic studies revealed that an allelic loss of the interferon-beta gene (IFNbeta-1) and an endogenous type of mutation of the @entity4 antioncogene were found only in the @entity1 . Mutations were not observed in the ras, neu, or multiple @entity1 suppressor ( @entity6 / @entity6 ) genes in any specimens. The authors' data indicated that the @entity4 genetic mutation was associated with integration of HPV-11 in histologically @entity1 . This association may promote a progressive genetic instability that can lead to the development and clonal expansion of @entity1 in @entity9 .

title: Malignant transformation of recurrent XXXX associated with integrated @entity7 type 11 DNA and mutation of @entity4 .

answer: @entity9


abstract: We have adopted @entity2 as a sclerosing agent in the treatment of cystic predominant thyroid nodules and have analyzed our findings to assess the efficacy of intralesional instillation of @entity2 . From 1992 through 1993, 48 @entity0 with recurrent or progressive cystic thyroid nodules after 2 or 3 aspirations alone, and whom were cytologically negative for @entity1 , were used for this study. The @entity2 solution was prepared by dissolving 0.1 mg of @entity2 in 2 ml of physiologic saline and it was instilled in the amount of 1/10-to-1/5 of the aspirated cystic fluid. A repeated course of therapy was given up to 3 times when sufficient resolution was not obtained 4-to-6 weeks after treatment. The mean number of treatment sessions per @entity0 was 1.5. Throughout the follow-up period from 30-to-45 months (mean, 38 months), 32 (66.7%) @entity0 experienced an almost complete disappearance (< 0.05 cm in diameter) of the @entity3 , and 12 (25%) @entity0 responded partially by having it decrease by more than half (> 0.5 cm in diameter) of the initial cyst size, and none of these @entity0 required further treatment. The remaining 4 (8.3%) @entity0 showed insufficient resolution despite 3 courses of therapy and 2 of these @entity0 underwent thyroidectomy, in which the lesion proved benign in both cases. All of the @entity0 tolerated the sclerotherapy well. No significant local complications attributed to this treatment were observed. However, a low-grade fever was observed in 26 (54.2%) @entity0 for 2 to 5 days after instillation, which subsided with symptomatic treatment. On the basis of our experience, @entity2 sclerotherapy appears to be safe, simple and effective, and can be a useful alternative treatment for cystic thyroid nodules.

title: Sclerotherapy with XXXX for recurrent cystic thyroid nodule.

answer: @entity2


abstract: BACKGROUND: When severe symptoms of @entity3 persist despite medical management, surgery may be necessary. METHODS: A retrospective review was carried out of 81 @entity0 undergoing surgery for @entity3 in the 10-year period from 1984 to 1993 to determine the long-term outcome at a minimum follow-up of 12 months. Of the 81 @entity0 , 15 were excluded from further analysis (11 were followed up for less than 12 months, two died and two were lost to follow-up). Sixty-six @entity0 were studied (median age 38 (range 15-77) years; 53 female). Of these, 49 underwent rectopexy, nine Delorme's operation, two anterior resection and four creation of a stoma as the initial operation. RESULTS: At a median follow-up of 90 (range 12-177) months, the rectopexy had failed in 22 of 49 @entity0 ; 19 of these @entity0 underwent further surgery, including rectal resection with coloanal @entity1 (four with three failures), colostomy (11) and other procedures (four). Ultimately, 14 required a stoma. Constipation was the indication for a stoma in nine of the 11 @entity0 who had colostomy as the first procedure after failure of rectopexy. Nine @entity0 had Delorme's operation as the first procedure. At median follow-up of 38 (range 19-107) months, there were four failures. Two of these ultimately required a stoma. Of the seven @entity0 who underwent anterior resection as the initial or subsequent procedure, a stoma was finally necessary in four. Anterior resection used as a salvage procedure was not successful. The overall stoma rate was 30 per cent (20 @entity0 ). Of 11 symptoms assessed before operation only @entity2 and incomplete evacuation were related to a poor outcome following surgery. CONCLUSION: Antiprolapse operations result in a satisfactory long-term outcome in about 55-60 per cent of @entity0 having surgery for @entity3 . Results of anterior resection are disappointing.

title: Long-term clinical outcome of surgery for XXXX .

answer: @entity3


abstract: Nasal airway obstruction may exacerbate @entity3 and is difficult to quantify on clinical examination. In this study, we examined the relationship among nasal patency, the frequency of @entity3 events, and effective nasal continuous positive air pressures. Acoustic rhinometry was used as an objective measurement of nasal cross-sectional areas in 76 @entity0 without nasal symptoms who underwent study with diagnostic polysomnography because of @entity1 . @entity0 with @entity1 were titrated to nasal continuous positive air pressure in a split night study. All subjects had a mean @entity2 / @entity3 index of 28, and those with @entity1 had a mean @entity2 / @entity3 index of 43. Mean cross-sectional areas 1 to 4 cm into the nose were 1.7, 1.1, 2.1, and 2.8 cm2, respectively (F = 39, p < 0.001). However, there was no correlation between the @entity2 / @entity3 index and the cross-sectional area at the four distances (r = 0.03, 0.06, 0.02, and 0.02, respectively, p = not significant). Correlations between nasal continuous positive air pressures and cross-sectional areas did not reveal a significant relationship at any of the four sites (r = 0.09, 0.07, -0.03, 0.00, respectively). Findings in @entity0 with @entity2 were also compared with those in @entity0 without @entity2 and significant differences were not found (F = 0.019, p = not significant). Although it would seem intuitive that increased nasal obstruction is associated with the severity of @entity1 and difficulty with the use of nasal continuous positive air pressure, this study shows that nasal patency, as measured by acoustic rhinometry, does not correlate with the severity of @entity1 , as determined by the @entity2 / @entity3 index or the effective nasal continuous positive air pressure.

title: Nasal patency and the effectiveness of nasal continuous positive air pressure XXXX .

answer: @entity1


abstract: BACKGROUND: Identification of @entity1 antigens is crucial for the development of vaccination strategies against @entity3 ( @entity3 ). Most studies come from eastern-Asia, where @entity5 is the main cause of @entity3 . However, @entity1 antigen expression is poorly studied in low-endemic, western areas where the aetiology of @entity3 differs. METHODS: We constructed tissue microarrays from resected @entity3 tissue of 133 @entity0 . Expression of a comprehensive panel of @entity1 ( @entity8 , @entity17 , @entity16 , @entity9 , MAGE-C2, @entity12 , @entity14 , @entity15 ), onco-fetal ( @entity4 , @entity13 ) and @entity1 antigens ( @entity10 , @entity7 -1, Survivin, Midkine, @entity6 ) was determined by immunohistochemistry. RESULTS: A higher prevalence of MAGE antigens was observed in @entity0 with @entity5 . @entity0 with expression of more @entity1 antigens in general had better @entity3 -specific survival (P=0.022). The four @entity1 antigens with high expression in @entity3 and no, or weak, expression in surrounding @entity2 , were @entity10 , @entity13 , @entity9 and MAGE-C2, expressed in 90, 39, 17 and 20% of HCCs, respectively. Ninety-five percent of HCCs expressed at least one of these four @entity1 antigens. Interestingly, @entity13 was associated with @entity11 expression (P=0.001), an oncofetal transcription factor highly expressed in embryonal stem cells. @entity11 and @entity13 expression levels were correlated with vascular invasion, poor differentiation and higher @entity4 levels before surgery. Moreover, @entity0 who co-expressed higher levels of both @entity13 and @entity11 had worse @entity3 -specific survival (P=0.018). CONCLUSIONS: We describe a panel of four @entity1 antigens with excellent coverage and good @entity1 specificity in a western area, low-endemic for @entity5 . The association between @entity13 and @entity11 is a novel finding and suggests that @entity13 targeting may specifically attack the @entity1 stem-cell compartment.

title: Tumour antigen expression in XXXX in a low-endemic western area.

answer: @entity3


abstract: PSTPIP is a @entity0 -phosphorylated protein involved in the organization of the cytoskeleton. Its ectopic expression induces filipodial-like membrane extensions in NIH 3T3 cells. We previously observed a defect in cytokinesis and an increase in the @entity0 phosphorylation of PSTPIP in @entity4 -deficient fibroblasts. In this article, we demonstrate that @entity4 and PSTPIP are found in the same complexes in vivo and that they interact directly through the CTH domain of @entity4 and the coiled-coil domain of PSTPIP. We tested pathways that could regulate the @entity0 phosphorylation of PSTPIP. We found that the activation of the epidermal growth factor and platelet-derived growth factor receptors can induce PSTPIP phosphorylation. With the use of the @entity3 inhibitor, we demonstrate that @entity2 kinases are not involved in the epidermal growth factor-mediated phosphorylation of PSTPIP. Together with previous results, this suggests that @entity1 is the critical @entity0 kinase downstream of growth factor receptors responsible for PSTPIP phosphorylation. We also demonstrate that @entity4 dephosphorylates PSTPIP at @entity0 344. Importantly, we identified @entity0 344 as the main phosphorylation site of PSTPIP by performing tryptic phosphopeptide maps. This is an important finding since @entity0 367 of PSTPIP was also proposed as a candidate phosphorylation site involved in the negative regulation of the association between PSTPIP and @entity5 . In this respect, we observed that the PSTPIP. @entity5 complex is stable in vivo and is not affected by the phosphorylation of PSTPIP. Furthermore, we demonstrate that PSTPIP serves as a scaffold protein between @entity4 and @entity5 and allows @entity4 to dephosphorylate @entity5 . This finding suggests a possible mechanism for @entity4 to directly modulate actin remodeling through the PSTPIP- @entity5 interaction.

title: PSTPIP is a substrate of XXXX and serves as a scaffold guiding @entity4 toward a specific dephosphorylation of @entity5 .

answer: @entity4


abstract: PSTPIP is a @entity0 -phosphorylated protein involved in the organization of the cytoskeleton. Its ectopic expression induces filipodial-like membrane extensions in NIH 3T3 cells. We previously observed a defect in cytokinesis and an increase in the @entity0 phosphorylation of PSTPIP in @entity4 -deficient fibroblasts. In this article, we demonstrate that @entity4 and PSTPIP are found in the same complexes in vivo and that they interact directly through the CTH domain of @entity4 and the coiled-coil domain of PSTPIP. We tested pathways that could regulate the @entity0 phosphorylation of PSTPIP. We found that the activation of the epidermal growth factor and platelet-derived growth factor receptors can induce PSTPIP phosphorylation. With the use of the @entity3 inhibitor, we demonstrate that @entity2 kinases are not involved in the epidermal growth factor-mediated phosphorylation of PSTPIP. Together with previous results, this suggests that @entity1 is the critical @entity0 kinase downstream of growth factor receptors responsible for PSTPIP phosphorylation. We also demonstrate that @entity4 dephosphorylates PSTPIP at @entity0 344. Importantly, we identified @entity0 344 as the main phosphorylation site of PSTPIP by performing tryptic phosphopeptide maps. This is an important finding since @entity0 367 of PSTPIP was also proposed as a candidate phosphorylation site involved in the negative regulation of the association between PSTPIP and @entity5 . In this respect, we observed that the PSTPIP. @entity5 complex is stable in vivo and is not affected by the phosphorylation of PSTPIP. Furthermore, we demonstrate that PSTPIP serves as a scaffold protein between @entity4 and @entity5 and allows @entity4 to dephosphorylate @entity5 . This finding suggests a possible mechanism for @entity4 to directly modulate actin remodeling through the PSTPIP- @entity5 interaction.

title: PSTPIP is a substrate of @entity4 and serves as a scaffold guiding XXXX toward a specific dephosphorylation of @entity5 .

answer: @entity4


abstract: PSTPIP is a @entity0 -phosphorylated protein involved in the organization of the cytoskeleton. Its ectopic expression induces filipodial-like membrane extensions in NIH 3T3 cells. We previously observed a defect in cytokinesis and an increase in the @entity0 phosphorylation of PSTPIP in @entity4 -deficient fibroblasts. In this article, we demonstrate that @entity4 and PSTPIP are found in the same complexes in vivo and that they interact directly through the CTH domain of @entity4 and the coiled-coil domain of PSTPIP. We tested pathways that could regulate the @entity0 phosphorylation of PSTPIP. We found that the activation of the epidermal growth factor and platelet-derived growth factor receptors can induce PSTPIP phosphorylation. With the use of the @entity3 inhibitor, we demonstrate that @entity2 kinases are not involved in the epidermal growth factor-mediated phosphorylation of PSTPIP. Together with previous results, this suggests that @entity1 is the critical @entity0 kinase downstream of growth factor receptors responsible for PSTPIP phosphorylation. We also demonstrate that @entity4 dephosphorylates PSTPIP at @entity0 344. Importantly, we identified @entity0 344 as the main phosphorylation site of PSTPIP by performing tryptic phosphopeptide maps. This is an important finding since @entity0 367 of PSTPIP was also proposed as a candidate phosphorylation site involved in the negative regulation of the association between PSTPIP and @entity5 . In this respect, we observed that the PSTPIP. @entity5 complex is stable in vivo and is not affected by the phosphorylation of PSTPIP. Furthermore, we demonstrate that PSTPIP serves as a scaffold protein between @entity4 and @entity5 and allows @entity4 to dephosphorylate @entity5 . This finding suggests a possible mechanism for @entity4 to directly modulate actin remodeling through the PSTPIP- @entity5 interaction.

title: PSTPIP is a substrate of @entity4 and serves as a scaffold guiding @entity4 toward a specific dephosphorylation of XXXX .

answer: @entity5


abstract: The phospholipid-binding plasma protein @entity3 ( @entity3 ) is the primary antigen recognized by the circulating autoantibodies in @entity0 with the " @entity2 " ( @entity2 ). Although heparin is routinely used in the treatment and prophylaxis of @entity2 @entity0 , the primary heparin-binding site within @entity3 has not been identified. More importantly, how heparin exerts its beneficial effects in vivo in @entity2 @entity0 has not been deduced at the molecular level. Using an expression/site-directed mutagenesis approach, we now show that the positively charged site that resides in the first domain of @entity3 is not the primary heparin-binding site. Rather it is the second positively charged site located within the fifth domain of the protein that also binds to phospholipids. Lys(284), Lys(286), and Lys(287) in this domain are essential for the interaction of @entity3 with heparin. These data indicate that @entity3 binds to heparin in a relatively specific manner even though the affinity for the interaction is rather low. Lys(317) resides in the center of the high affinity phospholipid-binding site. Surprisingly, heparin at concentrations that can be achieved in vivo during anticoagulation therapy greatly enhances the @entity1 -mediated cleavage of the Lys(317)-Thr(318) site in @entity3 . Because the cleaved form cannot bind to phospholipids effectively, the combined actions of heparin and @entity1 result in a diminished ability of @entity3 to recognize phospholipids. This, in turn, decreases the prothrombotic activity of the endogenous circulating anti- @entity3 antibodies in the @entity0 . Thus, heparin exerts its beneficial effects in @entity2 @entity0 by at least two distinct mechanisms.

title: Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the XXXX -mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in @entity0 with the @entity2 .

answer: @entity1


abstract: The phospholipid-binding plasma protein @entity3 ( @entity3 ) is the primary antigen recognized by the circulating autoantibodies in @entity0 with the " @entity2 " ( @entity2 ). Although heparin is routinely used in the treatment and prophylaxis of @entity2 @entity0 , the primary heparin-binding site within @entity3 has not been identified. More importantly, how heparin exerts its beneficial effects in vivo in @entity2 @entity0 has not been deduced at the molecular level. Using an expression/site-directed mutagenesis approach, we now show that the positively charged site that resides in the first domain of @entity3 is not the primary heparin-binding site. Rather it is the second positively charged site located within the fifth domain of the protein that also binds to phospholipids. Lys(284), Lys(286), and Lys(287) in this domain are essential for the interaction of @entity3 with heparin. These data indicate that @entity3 binds to heparin in a relatively specific manner even though the affinity for the interaction is rather low. Lys(317) resides in the center of the high affinity phospholipid-binding site. Surprisingly, heparin at concentrations that can be achieved in vivo during anticoagulation therapy greatly enhances the @entity1 -mediated cleavage of the Lys(317)-Thr(318) site in @entity3 . Because the cleaved form cannot bind to phospholipids effectively, the combined actions of heparin and @entity1 result in a diminished ability of @entity3 to recognize phospholipids. This, in turn, decreases the prothrombotic activity of the endogenous circulating anti- @entity3 antibodies in the @entity0 . Thus, heparin exerts its beneficial effects in @entity2 @entity0 by at least two distinct mechanisms.

title: Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the @entity1 -mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in @entity0 with the XXXX .

answer: @entity2


abstract: The phospholipid-binding plasma protein @entity3 ( @entity3 ) is the primary antigen recognized by the circulating autoantibodies in @entity0 with the " @entity2 " ( @entity2 ). Although heparin is routinely used in the treatment and prophylaxis of @entity2 @entity0 , the primary heparin-binding site within @entity3 has not been identified. More importantly, how heparin exerts its beneficial effects in vivo in @entity2 @entity0 has not been deduced at the molecular level. Using an expression/site-directed mutagenesis approach, we now show that the positively charged site that resides in the first domain of @entity3 is not the primary heparin-binding site. Rather it is the second positively charged site located within the fifth domain of the protein that also binds to phospholipids. Lys(284), Lys(286), and Lys(287) in this domain are essential for the interaction of @entity3 with heparin. These data indicate that @entity3 binds to heparin in a relatively specific manner even though the affinity for the interaction is rather low. Lys(317) resides in the center of the high affinity phospholipid-binding site. Surprisingly, heparin at concentrations that can be achieved in vivo during anticoagulation therapy greatly enhances the @entity1 -mediated cleavage of the Lys(317)-Thr(318) site in @entity3 . Because the cleaved form cannot bind to phospholipids effectively, the combined actions of heparin and @entity1 result in a diminished ability of @entity3 to recognize phospholipids. This, in turn, decreases the prothrombotic activity of the endogenous circulating anti- @entity3 antibodies in the @entity0 . Thus, heparin exerts its beneficial effects in @entity2 @entity0 by at least two distinct mechanisms.

title: Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the @entity1 -mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in XXXX with the @entity2 .

answer: @entity0


abstract: UNASSIGNED: Obesity is a serious worldwide disease, which is growing in epidemic proportions. Adipose-derived stem cells (ADSCs) are characterized as a source of mesenchymal stem cells that have acted as a potential application for regeneration. Recently, seaweeds rich in @entity5 and polysaccharides have been supposed to show the ability to modulate risk factors for @entity2 and @entity3 . In the present study, we investigated the anti- @entity2 properties of high stability @entity7 (HS-Fx) derived from brown seaweeds on the adipogenesis of ADSCs upon treatment with @entity6 (PA). First, we showed the differentiation capability of ADSCs from morbid @entity2 @entity0 to transform into different cell types. Second, we found that the co-treatment of ADSCs with HS-Fx and PA showed no significant @entity4 against ADSCs, but PA induced the elevation of reactive @entity1 species (ROS) and lipid droplet accumulation was abolished. Thirdly, the PA-mediated down-regulation of lipid metabolism genes was reversed by the treatment of HS-Fx. By long non-coding RNAs (lncRNAs) screening, we found that PA-induced increases in the targeted lncRNAs were also decreased upon treatment with HS-Fx. On Silencing, these lncRNAs corresponded to the decrease in the lipid droplet accumulation of ADSCs induced by PA. ADSCs from @entity2 @entity0 would be direct and meaningful model cells to investigate the development of @entity2 and their treatments, rather than cell lines from other species. HS-Fx showed anti- @entity2 capability through modulating the elevation of ROS, down-regulation of lipid metabolism genes induced by PA, and upstream signaling, which might be critically resulted from the expression of lncRNAs.

title: Inhibitory effects of high stability XXXX on @entity6 -induced lipid accumulation in @entity0 adipose-derived stem cells through modulation of long non-coding RNA.

answer: @entity7


abstract: UNASSIGNED: Obesity is a serious worldwide disease, which is growing in epidemic proportions. Adipose-derived stem cells (ADSCs) are characterized as a source of mesenchymal stem cells that have acted as a potential application for regeneration. Recently, seaweeds rich in @entity5 and polysaccharides have been supposed to show the ability to modulate risk factors for @entity2 and @entity3 . In the present study, we investigated the anti- @entity2 properties of high stability @entity7 (HS-Fx) derived from brown seaweeds on the adipogenesis of ADSCs upon treatment with @entity6 (PA). First, we showed the differentiation capability of ADSCs from morbid @entity2 @entity0 to transform into different cell types. Second, we found that the co-treatment of ADSCs with HS-Fx and PA showed no significant @entity4 against ADSCs, but PA induced the elevation of reactive @entity1 species (ROS) and lipid droplet accumulation was abolished. Thirdly, the PA-mediated down-regulation of lipid metabolism genes was reversed by the treatment of HS-Fx. By long non-coding RNAs (lncRNAs) screening, we found that PA-induced increases in the targeted lncRNAs were also decreased upon treatment with HS-Fx. On Silencing, these lncRNAs corresponded to the decrease in the lipid droplet accumulation of ADSCs induced by PA. ADSCs from @entity2 @entity0 would be direct and meaningful model cells to investigate the development of @entity2 and their treatments, rather than cell lines from other species. HS-Fx showed anti- @entity2 capability through modulating the elevation of ROS, down-regulation of lipid metabolism genes induced by PA, and upstream signaling, which might be critically resulted from the expression of lncRNAs.

title: Inhibitory effects of high stability @entity7 on XXXX -induced lipid accumulation in @entity0 adipose-derived stem cells through modulation of long non-coding RNA.

answer: @entity6


abstract: UNASSIGNED: Obesity is a serious worldwide disease, which is growing in epidemic proportions. Adipose-derived stem cells (ADSCs) are characterized as a source of mesenchymal stem cells that have acted as a potential application for regeneration. Recently, seaweeds rich in @entity5 and polysaccharides have been supposed to show the ability to modulate risk factors for @entity2 and @entity3 . In the present study, we investigated the anti- @entity2 properties of high stability @entity7 (HS-Fx) derived from brown seaweeds on the adipogenesis of ADSCs upon treatment with @entity6 (PA). First, we showed the differentiation capability of ADSCs from morbid @entity2 @entity0 to transform into different cell types. Second, we found that the co-treatment of ADSCs with HS-Fx and PA showed no significant @entity4 against ADSCs, but PA induced the elevation of reactive @entity1 species (ROS) and lipid droplet accumulation was abolished. Thirdly, the PA-mediated down-regulation of lipid metabolism genes was reversed by the treatment of HS-Fx. By long non-coding RNAs (lncRNAs) screening, we found that PA-induced increases in the targeted lncRNAs were also decreased upon treatment with HS-Fx. On Silencing, these lncRNAs corresponded to the decrease in the lipid droplet accumulation of ADSCs induced by PA. ADSCs from @entity2 @entity0 would be direct and meaningful model cells to investigate the development of @entity2 and their treatments, rather than cell lines from other species. HS-Fx showed anti- @entity2 capability through modulating the elevation of ROS, down-regulation of lipid metabolism genes induced by PA, and upstream signaling, which might be critically resulted from the expression of lncRNAs.

title: Inhibitory effects of high stability @entity7 on @entity6 -induced lipid accumulation in XXXX adipose-derived stem cells through modulation of long non-coding RNA.

answer: @entity0


abstract: Older individuals (subjects aged >65 years) largely contribute to the percentage @entity7 due to @entity11 ( @entity11 ) and @entity2 . The incidence of @entity15 ( @entity15 ) is also higher >65 years old @entity0 . However, the risk of @entity10 complications in patients on antithrombotic drugs increases with age and with clinical conditions, as @entity6 , @entity5 , @entity3 , poor compliance with medications, common in the elderly. Thus the risk-benefit ratio of antithrombotics should be carefully evaluated in older individuals. To prevent the risk and the recurrence of @entity8 and @entity11 in the older @entity0 with stable/ @entity18 , @entity11 , @entity19 / @entity2 or peripheral @entity9 , antiplatelet drugs are of choice. @entity4 is the most widely used antiplatelet drug. @entity17 is safer and more effective than @entity4 in this respect. The combination of heparin and @entity4 is the treatment of choice for @entity18 and @entity11 , also in the elderly. Low molecular weight heparins (LMWHs) proved to be as effective as standard heparin in this indication. In the absence of contraindications, thrombolysis for treatment of @entity11 may be considered in the elderly. For the treatment of @entity15 ( @entity15 ), intravenous standard heparin, subcutaneous standard heparin or LMWHs are effective. Because of the limited risk/benefit ratio, thrombolytic agents are not recommended for treating @entity13 ( @entity13 ) in the elderly. They should be limited to young @entity0 and to @entity0 with massive @entity14 ( @entity14 ). For chronic treatment of @entity15 , @entity16 is the treatment of choice (INR 2.0-3.0), also in the elderly. Because of @entity1 to oral anticoagulants, lower dosages of @entity16 are needed in the old @entity0 . As to prophylaxis of @entity15 in surgery, in subjects at low-moderate risk, or in medical @entity0 , low-dose heparin or low-dose LMWHs are effective. As to prophylaxis of @entity15 in surgery in subjects at high risk, adjusted-dose heparin or high-dose LMWHs are recommended. Finally, as to prevention of @entity2 in @entity0 older than 75 with @entity12 ( @entity12 ), @entity16 is of choice.

title: The use of antithrombotic drugs in older XXXX .

answer: @entity0


abstract: BACKGROUND: Although intentional weight reduction improves obesity-related comorbidities, the associations between weight reduction, medication and related costs are rarely studied. This study investigates the long-term effects of weight change on medication for @entity1 and @entity3 ( @entity3 ) in severely @entity2 subjects. METHODS: In the intervention study Swedish Obese Subjects, 510 surgically and 455 conventionally treated @entity2 @entity0 have so far been followed for 6 y. Changes in the use and costs of medication were analyzed in relation to treatment and weight change. RESULTS: In comparison with controls, larger fraction of surgically treated @entity0 discontinued the use of medication for @entity3 and @entity1 at 2 and 6 y (risk ratios 0.56-0.77). Among subjects not initially on medication, surgery reduced the frequency of started treatments (risk ratios 0.08-0.80). Relative @entity4 >or=10% was necessary to reduce costs of medication for @entity3 and @entity1 among subjects with such treatment at baseline. To reduce initiation of new treatment against the two conditions, @entity4 >or=15% was required. Over 6 y, the average annual cost for @entity1 and @entity3 medication increased by 463 SEK (96%) in subjects with @entity4 <5%, and decreased by 39 SEK(8%) in the @entity4 group >or=15%. CONCLUSION: Long-term intentional @entity4 is associated with reduced medication and medication costs for @entity1 and @entity3 . The effects appear to be more marked among subjects who are initially on medication for these conditions, whereas greater weight reduction is needed to prevent new subjects from starting on medication.

title: Long-term effects of XXXX on pharmaceutical costs in @entity2 subjects. A report from the SOS intervention study.

answer: @entity4


abstract: BACKGROUND: Although intentional weight reduction improves obesity-related comorbidities, the associations between weight reduction, medication and related costs are rarely studied. This study investigates the long-term effects of weight change on medication for @entity1 and @entity3 ( @entity3 ) in severely @entity2 subjects. METHODS: In the intervention study Swedish Obese Subjects, 510 surgically and 455 conventionally treated @entity2 @entity0 have so far been followed for 6 y. Changes in the use and costs of medication were analyzed in relation to treatment and weight change. RESULTS: In comparison with controls, larger fraction of surgically treated @entity0 discontinued the use of medication for @entity3 and @entity1 at 2 and 6 y (risk ratios 0.56-0.77). Among subjects not initially on medication, surgery reduced the frequency of started treatments (risk ratios 0.08-0.80). Relative @entity4 >or=10% was necessary to reduce costs of medication for @entity3 and @entity1 among subjects with such treatment at baseline. To reduce initiation of new treatment against the two conditions, @entity4 >or=15% was required. Over 6 y, the average annual cost for @entity1 and @entity3 medication increased by 463 SEK (96%) in subjects with @entity4 <5%, and decreased by 39 SEK(8%) in the @entity4 group >or=15%. CONCLUSION: Long-term intentional @entity4 is associated with reduced medication and medication costs for @entity1 and @entity3 . The effects appear to be more marked among subjects who are initially on medication for these conditions, whereas greater weight reduction is needed to prevent new subjects from starting on medication.

title: Long-term effects of @entity4 on pharmaceutical costs in XXXX subjects. A report from the SOS intervention study.

answer: @entity2


abstract: PURPOSE: Pelvic organ prolapse results in a spectrum of progressively disabling disorders. Despite attempts to standardize the clinical examination, a variety of imaging techniques are used. The purpose of this study was to evaluate dynamic pelvic magnetic resonance imaging and dynamic cystocolpoproctography in the surgical management of females with @entity3 . METHODS: Twenty-two @entity0 were identified from The Johns Hopkins @entity3 Center database who had symptoms of complex pelvic organ prolapse and underwent dynamic magnetic resonance, dynamic cystocolpoproctography, and subsequent multidisciplinary review and operative repair. RESULTS: The mean age of the study group was 58 +/- 13 years, and all @entity0 were Caucasian. Constipation (95.5 percent), @entity1 (77.3 percent), complaints of incomplete fecal evacuation (59.1 percent), and bulging vaginal tissues (54.4 percent) were the most common complaints on presentation. All @entity0 had multiple complaints with a median number of 4 symptoms (range, 2-8). Physical examination, dynamic magnetic resonance imaging, and dynamic cystocolpoproctography were concordant for rectocele, enterocele, cystocele, and perineal descent in only 41 percent of @entity0 . Dynamic imaging lead to changes in the initial operative plan in 41 percent of @entity0 . Dynamic magnetic resonance was the only modality that identified levator ani @entity2 . Dynamic cystocolpoproctography identified sigmoidoceles and internal rectal prolapse more often than physical examination or dynamic magnetic resonance. CONCLUSIONS: Levator ani @entity2 are often missed by physical examination and traditional fluoroscopic imaging. Dynamic magnetic resonance and cystocolpoproctography are complementary studies to the physical examination that may alter the surgical management of females with @entity3 .

title: Dynamic pelvic magnetic resonance imaging and cystocolpoproctography alter surgical management of XXXX .

answer: @entity3


abstract: BACKGROUND AND OBJECTIVE: To compare subfoveal @entity4 ( @entity4 ) measurements in eyes with nonexudative @entity2 ( @entity2 ) in the presence or absence of @entity3 ( @entity3 ). @entity0 AND METHODS: Subfoveal @entity4 measurements obtained from @entity0 with @entity2 enrolled in the COMPLETE study (30 @entity1 with @entity5 [ @entity5 ]) were compared with an age-distributed normal control group. Multimodal images were evaluated to detect the presence of @entity3 . RESULTS: After controlling for age and axial length, the mean @entity4 was significantly thinner in the @entity5 group with @entity3 (213.7    53.1   m) than in the @entity5 group without @entity3 (335.3    123.2   m; P = .001). The mean @entity4 in the @entity5 group without @entity3 was not statistically different from the mean @entity4 in the normal control group (P = .076) or the drusen group without @entity3 (P = .45). In eyes without @entity3 , there was a correlation between the increasing size of @entity5 and a decrease in @entity4 measurements. CONCLUSION: Subfoveal choroidal thinning in eyes with nonexudative @entity2 was associated with the presence of @entity3 . In the absence of @entity3 , @entity4 only decreased as the size of @entity5 increased. [Ophthalmic Surg Lasers Imaging Retina. 2015;46:513-521.].

title: Association Between Subfoveal Choroidal Thickness, Reticular Pseudodrusen, and XXXX in Age-Related @entity2 .

answer: @entity5


abstract: BACKGROUND AND OBJECTIVE: To compare subfoveal @entity4 ( @entity4 ) measurements in eyes with nonexudative @entity2 ( @entity2 ) in the presence or absence of @entity3 ( @entity3 ). @entity0 AND METHODS: Subfoveal @entity4 measurements obtained from @entity0 with @entity2 enrolled in the COMPLETE study (30 @entity1 with @entity5 [ @entity5 ]) were compared with an age-distributed normal control group. Multimodal images were evaluated to detect the presence of @entity3 . RESULTS: After controlling for age and axial length, the mean @entity4 was significantly thinner in the @entity5 group with @entity3 (213.7    53.1   m) than in the @entity5 group without @entity3 (335.3    123.2   m; P = .001). The mean @entity4 in the @entity5 group without @entity3 was not statistically different from the mean @entity4 in the normal control group (P = .076) or the drusen group without @entity3 (P = .45). In eyes without @entity3 , there was a correlation between the increasing size of @entity5 and a decrease in @entity4 measurements. CONCLUSION: Subfoveal choroidal thinning in eyes with nonexudative @entity2 was associated with the presence of @entity3 . In the absence of @entity3 , @entity4 only decreased as the size of @entity5 increased. [Ophthalmic Surg Lasers Imaging Retina. 2015;46:513-521.].

title: Association Between Subfoveal Choroidal Thickness, Reticular Pseudodrusen, and @entity5 in Age-Related XXXX .

answer: @entity2


abstract: Cranial @entity0 remains a major challenge to craniofacial surgeons because of limited availability of autologous bone graft to repair the defects and the donor site defects secondary to tissue harvesting. In contrast, tissue-engineering technique can generate a large bone tissue using small amount of autologous cells and therefore avoid these problems. Bone Marrow Stromal Cells (MSCs) have the potential of multi-lineage (including osteogenic) differentiation. The objective of this study was to investigate the potential of using autologous MSCs to repair cranial bone defects by a tissue-engineering approach. Autologous MSCs were isolated from eight adult @entity3 respectively and were in vitro expanded and induced to become osteogenic cells. Bilateral full-thickness defects (20 mm in diameter) of parietal bones were created in animals and the bone defects were either repaired with the bone implants constituted with MSCs and @entity4 at the experimental side (n = 8) or treated with @entity2 alginate only without MSCs (n = 4) or left unrepaired (n = 4) at the control side. New bone tissues were observed either grossly or histologically at the defects of experimental group as early as 6 weeks post-repairing, but not in control groups. The engineered bone tissue became more mature at 18 weeks post-repairing. Three-dimensional computerized tomography (CT) scan revealed an almost complete repair of the defect of experimental group at 18 weeks. This study may provide insight for future clinical repair of @entity1 .

title: Tissue-engineered bone repair of XXXX @entity1 with autologous bone marrow stromal cells.

answer: @entity3


abstract: Cranial @entity0 remains a major challenge to craniofacial surgeons because of limited availability of autologous bone graft to repair the defects and the donor site defects secondary to tissue harvesting. In contrast, tissue-engineering technique can generate a large bone tissue using small amount of autologous cells and therefore avoid these problems. Bone Marrow Stromal Cells (MSCs) have the potential of multi-lineage (including osteogenic) differentiation. The objective of this study was to investigate the potential of using autologous MSCs to repair cranial bone defects by a tissue-engineering approach. Autologous MSCs were isolated from eight adult @entity3 respectively and were in vitro expanded and induced to become osteogenic cells. Bilateral full-thickness defects (20 mm in diameter) of parietal bones were created in animals and the bone defects were either repaired with the bone implants constituted with MSCs and @entity4 at the experimental side (n = 8) or treated with @entity2 alginate only without MSCs (n = 4) or left unrepaired (n = 4) at the control side. New bone tissues were observed either grossly or histologically at the defects of experimental group as early as 6 weeks post-repairing, but not in control groups. The engineered bone tissue became more mature at 18 weeks post-repairing. Three-dimensional computerized tomography (CT) scan revealed an almost complete repair of the defect of experimental group at 18 weeks. This study may provide insight for future clinical repair of @entity1 .

title: Tissue-engineered bone repair of @entity3 XXXX with autologous bone marrow stromal cells.

answer: @entity1


abstract: Facial infiltrating @entity6 is a rare @entity5 in which mature lipocytes invade adjacent tissue. The phenotypic features include soft-tissue and skeletal @entity3 , @entity1 , and regional @entity10 . There is a high risk for regrowth after resection that is, perforce, subtotal. The etiology, natural history, optimal management, and relationship to other @entity7 are unclear. In this study, the clinical features, radiographic findings, histopathology, and postoperative results were analyzed in 13 @entity0 with facial infiltrating @entity6 . The condition was diagnosed in infancy (eight male subjects, five female subjects) and characterized by enlargement of the cheek (n = 12) or chin (n = 1). Other findings included cutaneous @entity4 (n = 9), @entity8 (n = 8), and @entity9 (n = 6). Most @entity0 had early eruption of ipsilateral deciduous and permanent teeth (n = 12). Computed tomography and magnetic resonance imaging showed an infiltrated soft-tissue mass of fatty density (n = 13) and skeletal overgrowth (n = 9). Multiple resection was performed on six @entity0 (mean number of operations per @entity0 , 2.5; range, one to six operations); regrowth and/or worsening of the capillary stain occurred in all six @entity0 . Because surgical removal of the mass is usually unsuccessful, specific management of this condition will require insight into its etiopathogenesis. Given the presence of @entity9 and @entity6 , this study included testing for the known mutations in three entities that are associated with these soft-tissue findings ( @entity2 , @entity2 , and @entity9 ). Results of DNA analyses for these germline mutations were negative. It is more likely that this disorder is caused by a somatic mutation involving a local increase in growth factor(s).

title: Facial infiltrating XXXX .

answer: @entity6


abstract: Telomeres that guard chromosomes are shortened with each cell division because of replication-dependent sequence loss at both termini. The gradual erosion of telomeric length has been directly related to the process of aging in vivo. Recently we have reported, in @entity2 and @entity0 @entity1 cells treated with different apoptogens, cleavage and extrusion of telomeric DNA prior to cell death on one hand and an amplification of telomeric DNA in metastatic @entity1 of different histopathologic origin on the other. This study tested our hypothesis that telomere cleavage is linked to transplant rejection in @entity1 @entity0 receiving stem cells either from bone marrow (BM) or umbilical cord blood transfusion. Telomere integrity and mitotic catastrophe were studied by cytogenetic and molecular fluorescence in situ hybridization (FISH) techniques in two BM samples taken from a male stem cell transplant recipient diagnosed with @entity3 . The first BM sample, which was aspirated 27 days after transplant, was mitotically active. Only one of 50 metaphases showed a chromatid break. Every cell karyotyped was of male origin with 46, XY chromosome constitution. The second BM sample aspirated 52 days after transplant gave no metaphases and most interphase cells appeared dead. FISH preparations of the second BM sample showed cleavage and drastic reduction of telomeric DNA at the time the @entity0 was rejecting the transplant. In contrast, the first BM sample had shown no indication of cleavage of the telomeric DNA, although the percentage of telomeric area was smaller than in the control. The replicative stress imposed on the stem cells engrafted may result in an accelerated aging effect, possibly due to the erosion of telomeric DNA. We, therefore, conclude that BM rejection could be directly associated with the cleavage, clustering, and extrusion of telomeric DNA in the donor cells.

title: XXXX bone marrow transplant rejection is associated with telomere cleavage.

answer: @entity0


abstract: @entity3 is characterized by an impaired visual control of the direction of arm reaching to a visual target, accompanied by @entity1 and grip formation. In @entity0 , @entity3 is associated with lesions of the superior parietal lobule (SPL), which also affect visually guided saccades and other @entity2 . In the last 10 years, anatomical and physiological studies of the SPL have shed new light on the role of parietal cortex in the control of combined eye-hand movements to visual targets, and on the underlying distributed network which links parietal to frontal cortex. A main emerging functional feature of SPL neurones seems to be their capacity to combine, in a spatially congruent fashion, different directional eye- and hand-related information, that any coding scheme so far proposed, considers essential for the composition of motor commands for reaching. This integration occurs within the global tuning field of parietal neurones, is context-dependent and involves eye and hand information that shares the same directional properties. Depending on task demands, this integration of signals can result in the representation of different reference frames for coordinated eye-hand movements. The dynamic operations occurring within the global tuning fields might depend, at least in part, on the reciprocal sets of association connections linking the SPL and the premotor areas of the frontal lobe. From this picture, the SPL emerges as both a main source of visual input to the frontal cortex and a key structure for visuomotor integration based on re-entrant signalling and, therefore, as a crucial node in the visual control of movement. It is hypothesized that in parietal @entity0 , the directional errors that characterize reaching are a consequence of the breakdown of the combination of directional eye and hand information within the global tuning fields of parietal neurones. In these @entity0 , the spatial match among information about target location, eye and hand position, and movement direction would be prevented, so as to impair the composition of visually guided eye-hand movements. This breakdown could be dependent, at least in part, on the failure of a re-entrant frontoparietal signalling, an obvious consequence of the degeneration of the cortico-cortical systems linking parietal and frontal cortex. Cortico-cortical connections are, in fact, essential for shaping the dynamic properties of cortical neurones.

title: XXXX as a result of the breakdown of the global tuning fields of parietal neurones.

answer: @entity3


abstract: OBJECTIVE: This study sought to determine whether @entity0 with @entity7 ( @entity7 ) and @entity5 responded to treatment with @entity6 . METHODS: This was a post hoc analysis of a subgroup of @entity0 with @entity7 included in a larger double-blind, placebo-controlled, randomized parallel group trial of @entity6 for the treatment of @entity5 in @entity0 with @entity3 . @entity0 meeting the consensus criteria for @entity7 and exhibiting @entity4 and @entity8 were selected from the initial study. @entity5 was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). @entity1 were evaluated with the Simpson-Angus scale. RESULTS: Twenty-nine @entity0 met the criteria for @entity7 ; 10 were randomized to placebo, 5 received 5 mg of @entity6 , 7 received 10 mg of @entity6 and 7 received 15 mg of @entity6 . @entity0 with @entity7 treated with 5 mg of @entity6 showed significant reductions in delusions and @entity8 . @entity0 treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of @entity6 . There was no significant exacerbation of @entity4 in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic @entity2 did not differ among treatment groups. CONCLUSIONS: This preliminary analysis suggests that @entity6 (5 or 10 mg) reduces @entity5 in @entity0 with @entity7 without worsening @entity4 .

title: Efficacy of XXXX in the treatment of @entity5 in dementia with @entity7 .

answer: @entity6


abstract: OBJECTIVE: This study sought to determine whether @entity0 with @entity7 ( @entity7 ) and @entity5 responded to treatment with @entity6 . METHODS: This was a post hoc analysis of a subgroup of @entity0 with @entity7 included in a larger double-blind, placebo-controlled, randomized parallel group trial of @entity6 for the treatment of @entity5 in @entity0 with @entity3 . @entity0 meeting the consensus criteria for @entity7 and exhibiting @entity4 and @entity8 were selected from the initial study. @entity5 was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). @entity1 were evaluated with the Simpson-Angus scale. RESULTS: Twenty-nine @entity0 met the criteria for @entity7 ; 10 were randomized to placebo, 5 received 5 mg of @entity6 , 7 received 10 mg of @entity6 and 7 received 15 mg of @entity6 . @entity0 with @entity7 treated with 5 mg of @entity6 showed significant reductions in delusions and @entity8 . @entity0 treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of @entity6 . There was no significant exacerbation of @entity4 in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic @entity2 did not differ among treatment groups. CONCLUSIONS: This preliminary analysis suggests that @entity6 (5 or 10 mg) reduces @entity5 in @entity0 with @entity7 without worsening @entity4 .

title: Efficacy of @entity6 in the treatment of @entity5 in dementia with XXXX .

answer: @entity7


abstract: OBJECTIVE: This study sought to determine whether @entity0 with @entity7 ( @entity7 ) and @entity5 responded to treatment with @entity6 . METHODS: This was a post hoc analysis of a subgroup of @entity0 with @entity7 included in a larger double-blind, placebo-controlled, randomized parallel group trial of @entity6 for the treatment of @entity5 in @entity0 with @entity3 . @entity0 meeting the consensus criteria for @entity7 and exhibiting @entity4 and @entity8 were selected from the initial study. @entity5 was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). @entity1 were evaluated with the Simpson-Angus scale. RESULTS: Twenty-nine @entity0 met the criteria for @entity7 ; 10 were randomized to placebo, 5 received 5 mg of @entity6 , 7 received 10 mg of @entity6 and 7 received 15 mg of @entity6 . @entity0 with @entity7 treated with 5 mg of @entity6 showed significant reductions in delusions and @entity8 . @entity0 treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of @entity6 . There was no significant exacerbation of @entity4 in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic @entity2 did not differ among treatment groups. CONCLUSIONS: This preliminary analysis suggests that @entity6 (5 or 10 mg) reduces @entity5 in @entity0 with @entity7 without worsening @entity4 .

title: Efficacy of @entity6 in the treatment of XXXX in dementia with @entity7 .

answer: @entity5


abstract: OBJECTIVE: To investigate the effect of urinary trypsin inhibitor ( @entity2 ) in @entity0 at risk for @entity1 with bulging membrane. METHODS: @entity0 who had developed a bulging membrane from 22 to 27 weeks and 6 days of gestation were studied. These cases were divided into two types based on the severity: those with a moderately developed bulging membrane like a 'dome' (dome type), and those with a membrane prolapsed into the vagina, resulting in an 'hourglass' shape (hourglass type). We compared the outcomes of treatment with or without @entity2 ( @entity2 group versus @entity2 ) in each type. Gestational age at delivery, birth weight, prolongation time from admission to delivery, and neonatal mortality rate were examined in each group. RESULTS: A total of 43 @entity0 with a bulging membrane were analyzed. In 21 @entity0 with the dome type, gestational age at delivery (the @entity2 group versus the @entity2 ; 30.4 +/- 5.0 versus 26.4 +/- 1.9 weeks, p < 0.05), birth weight (1,436.8 +/- 708.3 versus 882.8 +/- 261.6 g, p < 0.05) and neonatal mortality rate (0/13 versus 3/8, p < 0.05) were all significantly improved by the use of @entity2 . On the other hand, in 22 @entity0 with the hourglass type, there was no significant difference between the @entity2 group and the @entity2 . The overall prevalence of histological @entity3 was 60%. CONCLUSION: These results suggest that @entity2 therapy is very effective in @entity0 at risk for @entity1 with a moderately developed bulging membrane during the second trimester.

title: Effects of urinary trypsin inhibitor in @entity0 at risk for XXXX with a bulging fetal membrane.

answer: @entity1


abstract: OBJECTIVE: To investigate the effect of urinary trypsin inhibitor ( @entity2 ) in @entity0 at risk for @entity1 with bulging membrane. METHODS: @entity0 who had developed a bulging membrane from 22 to 27 weeks and 6 days of gestation were studied. These cases were divided into two types based on the severity: those with a moderately developed bulging membrane like a 'dome' (dome type), and those with a membrane prolapsed into the vagina, resulting in an 'hourglass' shape (hourglass type). We compared the outcomes of treatment with or without @entity2 ( @entity2 group versus @entity2 ) in each type. Gestational age at delivery, birth weight, prolongation time from admission to delivery, and neonatal mortality rate were examined in each group. RESULTS: A total of 43 @entity0 with a bulging membrane were analyzed. In 21 @entity0 with the dome type, gestational age at delivery (the @entity2 group versus the @entity2 ; 30.4 +/- 5.0 versus 26.4 +/- 1.9 weeks, p < 0.05), birth weight (1,436.8 +/- 708.3 versus 882.8 +/- 261.6 g, p < 0.05) and neonatal mortality rate (0/13 versus 3/8, p < 0.05) were all significantly improved by the use of @entity2 . On the other hand, in 22 @entity0 with the hourglass type, there was no significant difference between the @entity2 group and the @entity2 . The overall prevalence of histological @entity3 was 60%. CONCLUSION: These results suggest that @entity2 therapy is very effective in @entity0 at risk for @entity1 with a moderately developed bulging membrane during the second trimester.

title: Effects of urinary trypsin inhibitor in XXXX at risk for @entity1 with a bulging fetal membrane.

answer: @entity0


abstract: The aim of this study was to determine the influence of metabolic control of @entity1 on natriuresis, the effect of natriuretic peptides and renal @entity13 on the kidney and the participation of proximal and distal tubules in natriuresis. The study was done in 41 individuals: 27 @entity7 @entity0 and 14 healthy controls. The @entity0 were on insulin only, had normal blood pressure, and were prescribed a standard @entity1 diet without @entity6 or protein restriction. @entity1 @entity0 were assigned to subgroups, depending on the stage of @entity2 and level of metabolic control. Urine collection was done three times daily in all @entity0 . The first collection was done after 500 mg @entity10 (p.o.) and was followed by 10 mg amilorid (Midamor, Thomas Morson Pharmaceuticals). The third collection of urine was used to evaluate excretion of @entity12 . In addition to @entity6 , @entity5 , @entity3 and @entity4 clearances, excretion of renal @entity13 , and levels of microalbuminuria, @entity14 and glycated hemoglobin were also determined. @entity5 clearance was used to evaluate tubular @entity6 transport. The influence of diuretic peptides--ANP and urodilatin, on natriuresis was reflected by urinary @entity12 excretion. Function of the @entity13 -kinin system was studied on the basis of excretion of @entity13 . Amilorid was used to test the effect of blocking @entity11 -sensitive @entity6 channels in distal tubules on natriuresis (Tab. 1). A statistically significant decrease in mean @entity5 clearance was observed in @entity7 @entity0 as compared to healthy controls. @entity4 clearance was the same in both groups (Tab. 2). Lower @entity5 clearance was observed in the subgroup of @entity1 @entity0 with "silent" @entity2 . @entity1 @entity0 with "silent" and early @entity2 had significantly higher levels of fractional @entity6 reabsorption in the proximal tubule when compared with controls (Tab. 3). Moreover, lower daily excretion of @entity13 was observed in @entity0 with stage II @entity2 in comparison to the control group (Tab. 4). Amilorid uptake had no influence on urinary @entity13 . However, natriuresis after amilorid was significantly higher in @entity1 @entity0 than in controls. In conclusion, reabsorption in the proximal tubule is increased in @entity0 with "silent" @entity8 , as revealed by decreased @entity5 clearance and unchanged @entity4 clearance. @entity9 of the proximal tubule in stage II and III of @entity8 results in increased @entity6 reabsorption in the proximal tubule, as reflected by the increase in fractional @entity6 reabsorption in this tubule. Amilorid, a distal tubule blocker, reduces distal tubule activity independently of urinary @entity13 excretion. Elevated natriuresis was observed after amilorid without any change in urinary @entity13 excretion.

title: [Regulation of natriuresis in XXXX ].

answer: @entity8


abstract: INTRODUCTION: Our aim was to evaluate the results and the prognosis of @entity2 of the mobile part of the tongue stage T1-T2 treated by surgery and radiotherapy at the Institute Jules Bordet from January 1950 to 31th December 1993. METHODS: According to the classification TNM (UICC 1978) 165 consecutive @entity0 classified as follow: 73 T1No (stage I), 64 T2No (stage II), 7 T1N1 and 20 T2N1 (stage III) and 1 @entity0 T2N2 (stage IV). All @entity0 underwent surgery beforehand. 136 @entity0 received additional brachytherapy. RESULTS: In this study were included 117 @entity0 and 48 @entity0 with an average age of 60 years. The rate of relapse on the primary tumoral site amounted to 16,4% and the residual relapse to 40%. The survival note without relapse was evaluated respectively at 3 years in 67% of the @entity1 T1 (against 28% for the T2), at 5 years for 59% for @entity1 T1 (against 26% for T2). From the clinical point of view the survival rate without relapse was of 5 years for 61% of stage I, 29% of stage II and 24% of stage III. A more extensive investigation shows the statistic influence, such as age (p<0.004), size of the @entity1 (p<0.007) and its shape (p<0.0007) on the total survive rate. The state of the nodes (p<0.02) and the safety margins (p<0.04) are statistically less associated. The survival rate with no relapse according to a study considering statistical factors, is significantly influenced by the size (p<0.0002) and age (p<0.0003). CONCLUSION: T1-T2 stages of the mobile tongue are characterized by a limited local spread but a more regional spread and diversified therapeutic approach with prognostic factors influencing the survival rate without forgetting the part played by the TNM classification.

title: [Prognostic factors in XXXX of the mobile tongue classified as T1-T2].

answer: @entity2


abstract: OBJECTIVE: To describe a new treatment for @entity3 caused by subretinal fluid associated with circumscribed @entity4 . METHODS: Three @entity0 were treated with photodynamic therapy using @entity5 for injection ( @entity5 ; QLT Phototherapeutics Inc, Vancouver, British Columbia). All @entity0 had pretreatment and posttreatment @entity2 angiography and ultrasonography. Treatment parameters used were @entity5 , 6 mg/m(2), and laser light at 689 nm delivered at 50 J/cm(2) with an intensity of 600 mW/cm(2) for 83 seconds. RESULTS: All @entity0 had complete resolution of subretinal fluid within 2 weeks of treatment. Fluorescein angiography performed 2 to 4 weeks after treatment showed absence of @entity1 leakage. All eyes had reduced @entity1 thickness or complete flattening. Visual acuity was improved in each eye. Average follow-up was 5.3 months. No complications were noted. CONCLUSION: Photodynamic therapy with @entity5 is effective in eliminating subretinal fluid and improving vision in @entity0 with circumscribed @entity4 .

title: @entity4 treated with photodynamic therapy using XXXX .

answer: @entity5


abstract: OBJECTIVE: To describe a new treatment for @entity3 caused by subretinal fluid associated with circumscribed @entity4 . METHODS: Three @entity0 were treated with photodynamic therapy using @entity5 for injection ( @entity5 ; QLT Phototherapeutics Inc, Vancouver, British Columbia). All @entity0 had pretreatment and posttreatment @entity2 angiography and ultrasonography. Treatment parameters used were @entity5 , 6 mg/m(2), and laser light at 689 nm delivered at 50 J/cm(2) with an intensity of 600 mW/cm(2) for 83 seconds. RESULTS: All @entity0 had complete resolution of subretinal fluid within 2 weeks of treatment. Fluorescein angiography performed 2 to 4 weeks after treatment showed absence of @entity1 leakage. All eyes had reduced @entity1 thickness or complete flattening. Visual acuity was improved in each eye. Average follow-up was 5.3 months. No complications were noted. CONCLUSION: Photodynamic therapy with @entity5 is effective in eliminating subretinal fluid and improving vision in @entity0 with circumscribed @entity4 .

title: XXXX treated with photodynamic therapy using @entity5 .

answer: @entity4


abstract: OBJECTIVE: To investigate the risk factors of @entity1 . METHODS: A nested case-control study was conducted based on a cohort of 64,693 subjects in Jiashan county, Zhejiang, China. One hundred and ninety-six cases of @entity1 were detected during a follow-up program for 10 years. Nine hundred and eighty non- @entity1 subjects were randomly selected from the cohort as controls. Univariate analysis and mutivariate non-conditional logistic regression were used to analyse associations between the exposure factors and @entity1 . RESULTS: The age of case group was significantly older than that of the control group. Moreover, the age at diagnose of @entity2 was significantly older than that of the @entity0 . Other than age, the final regression model showed that mucous blood stool history and @entity3 history were significantly associated with @entity2 (OR = 2.961, 95% CI:1.202-7.298 and 8.941, 95% CI:1.820-43.926, respectively) while mixed sources of drinking water was found to be associated with @entity0 with a OR value of 1.823 (95% CI:1.024-3.247). CONCLUSION: The risk factors of @entity2 were different from that of the @entity0 . Age was an important factor influencing the incidence of both @entity2 and @entity0 . Mucous blood stool history and @entity3 history were associated with @entity2 , while drinking mixed water was closely associated with @entity0 .

title: [Nested case-control study on the risk factors of XXXX ].

answer: @entity1


abstract: BACKGROUND: Clinical evaluation is a multifactorial process producing as many clinical scores as there are clinical dimensions. For a medicoeconomical analysis however, a single global score would be most useful. The aim of this work was to examine methods allowing relative quantification of items on multidimensional clinical scores in order to determine an appropriate solution for weighted @entity3 . METHOD: Several techniques for item weighting, developed as part of a multi-criteria decision-making tool (AMCD Aide Multi-Crit  re    la D  cision), were examined. Two methods were applied to multidimensional assessment of disability in order to estimate the weight that should be assigned to each of its six items before aggregation in a unique score. The AHP method was used with an interview of 20 functional rehabilitation specialists. The Diakoulaki method was based on the observation of thirty @entity0 with @entity1 and in thirty @entity0 with vascular @entity2 . RESULTS: The three weighting schemes were very different from the uniform weighting and were not correlated with each other. The items best weighted by the AHP method were "physical independence" and "mobility". For the Diakoulaki method, they were "social integration" and "economic independence" for the @entity1 @entity0 , and "awareness of the outside world" and "economic independence" for the vascular @entity2 @entity0 . Application of these three weighting schemes to theoretical @entity0 produced very different assessments of global disability. CONCLUSIONS: Weighting schemes are useful to quantify the relative importance of individual clinical items. The choice of the weighting method is determinant and depends on the objective of the investigator. If the objective is a global score, the first step is to estimate the weight of the individual items, either when applying a validation process for a new multidimensional clinical score, or secondarily to adapt a validated score to a particular protocol.

title: [Management of multidimensional clinical scores: which solutions for XXXX ?].

answer: @entity3


abstract: Our aims were to itemize the clinical features and the outcome of @entity1 in the elderly, as well as any age and sex differences in its acquisition. Therefore, we compared the demographic and clinical data of 12 elderly (group 1) cases of @entity1 with 69 middle-aged @entity0 (group 2) and 12 @entity0 (group 3) suffering from the same disease. There was no significant difference between the site of entry and incubation period or in the clinical and paraclinical findings among the three groups of @entity0 . @entity2 was found more commonly in group 1 than in groups 2 and 3 (p = 0.0167 and p = 0.0006, respectively). It was also more common in group 2 than in group 3 (p = 0.0140). A mild form of @entity1 was more often detected in @entity0 than in middle-aged and elderly cases (p = 0.0213 and p = 0.0013, respectively). Severe @entity1 was seen more often in group 1 than in groups 2 and 3 (p = 0.0167 and p = 0.0006, respectively). Despite this, the mortality rate was not statistically different among the three groups of @entity0 . Females were affected much less frequently than males with a female:male ratio of 1:3 in all three age groups. Our results suggest that elderly @entity0 are at higher risk of acquiring a more severe form of @entity1 and the subsequent development of @entity2 . In addition, the disease is more common in males of all age groups, and age and sex have no apparent effect on the outcome of @entity0 with @entity1 .

title: XXXX in the elderly: is it different from that in younger age groups?

answer: @entity1


abstract: The vascular endothelium plays a central role in the regulation of the arterial tone and in the control of the local hemostasis. It is also involved in the regulation of proliferation processes of the vascular wall. The presence of risk factors for @entity1 and/or manifest @entity2 are associated with an impairment of endothelium-dependent vasoregulation. Since the assessment of coronary vascular reactivity requires an invasive approach, it would be desirable to non- or semi-invasively evaluate blood flow regulation and its impairment by @entity2 processes. Indeed, @entity0 of the coronary arteries parallels endothelium-related impairment of vasoreactivity of the brachial artery. Analysis of flow-dependent dilatation of the brachial artery by means of ultrasound represents a non-invasive diagnostic tool to assess endothelium-mediated vasomotion. By means of venous strain gauge forearm occlusion plethysmography, it is possible to measure the blood flow in a semi-invasive way. The endothelium-mediated forearm blood flow response is obtained by the infusion of @entity3 into the brachial artery, whereas infusion of @entity4 - @entity5 provides information about the endothelium-independent vasodilator capacity of the forearm resistance vasculature. Assuming that the @entity2 process is a generalized disease, the assessment of the forearm blood flow by venous strain gauge occlusion plethysmography may provide some information applicable to the coronary circulation. However, the proof of a positive correlation between the degree of the impaired forearm blood flow responses measured by occlusion plethysmography and the extent of @entity1 and its disturbed vasoregulation remains to be established.

title: [Analysis of forearm circulation--a substitute for diagnosis of XXXX ?].

answer: @entity1


abstract: We report a case complete @entity2 with severe @entity1 . The @entity0 was a @entity0 aged 2 years and 6 months with @entity3 who had undergone pulmonary artery banding (PAB) 2 years previously. Postoperative catheterization after PAB showed severe @entity1 . Pulmonary resistance values were 9.3 and 7.3 units at 1 year and 5 months and 1 year and 9 months respectively. We performed re-PAB and lung biopsy when the @entity0 was 2 years and 6 months old. The biopsy specimen at re-PAB classified as Heath-Edwards grade 3 and had an IPVD score of 1.7, indicating tolerance to radical operation. Six months after re-PAB, pulmonary vascular resistance decreased a level at which radical operation could be performed safely. Radical operation was performed 1 year and 4 months after re-PAB. The post operative course was uneventful, and @entity1 did not occur. The lung biopsy at the final operation was classified as Heath-Edwards grade 3, had an IPVD score of 1.1, and showed improvement when compared with the pathological findings at re-PAB.

title: [Repair of complete @entity2 with severe XXXX --effect of re-pulmonary artery banding and analysis of lung biopsy: a case report].

answer: @entity1


abstract: We report a case complete @entity2 with severe @entity1 . The @entity0 was a @entity0 aged 2 years and 6 months with @entity3 who had undergone pulmonary artery banding (PAB) 2 years previously. Postoperative catheterization after PAB showed severe @entity1 . Pulmonary resistance values were 9.3 and 7.3 units at 1 year and 5 months and 1 year and 9 months respectively. We performed re-PAB and lung biopsy when the @entity0 was 2 years and 6 months old. The biopsy specimen at re-PAB classified as Heath-Edwards grade 3 and had an IPVD score of 1.7, indicating tolerance to radical operation. Six months after re-PAB, pulmonary vascular resistance decreased a level at which radical operation could be performed safely. Radical operation was performed 1 year and 4 months after re-PAB. The post operative course was uneventful, and @entity1 did not occur. The lung biopsy at the final operation was classified as Heath-Edwards grade 3, had an IPVD score of 1.1, and showed improvement when compared with the pathological findings at re-PAB.

title: [Repair of complete XXXX with severe @entity1 --effect of re-pulmonary artery banding and analysis of lung biopsy: a case report].

answer: @entity2


abstract: GOALS: This study aims to investigate the safety and efficacy of prolonged adjuvant @entity4 chemotherapy on survival of @entity3 after D2 gastrectomy. BACKGROUND: Inadequate evidence is available on optimal duration of chemotherapy and the number of administered cycles is generally based on @entity0 responsiveness and individual tolerability as well as physician preferences. STUDY: We randomly assigned 307 @entity3 @entity0 after D2 gastrectomy between January 2006 and December 2010 to XELOX group and Prolonged group. XELOX consisted of a 2-h intravenous infusion of @entity5 130mg/mg on day 1 and oral @entity4 1000mg/m(2) twice daily on days 1-14 of a 3-week cycle for eight cycles in half a year. In Prolonged group, @entity0 underwent extra oral @entity4 1000mg/m(2) twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX. The disease-free survival and overall survival were compared. RESULTS: Significant differences were found in 3-year disease-free survival (Prolonged group 56.6%, XELOX group 48.4%, P=0.0357). Subgroup analysis by TNM staging showed that @entity0 with @entity1 in the Prolonged group had significantly higher DFS (50.00% vs 40.96, P=0.0178) and @entity6 (71.95% vs 57.83, P=0.0230) than that of @entity0 in the XELOX group. No grade 4 adverse effects or treatment-related @entity2 were reported. More @entity0 in the Prolonged group experienced @entity7 than in the XELOX group. CONCLUSIONS: Prolonged @entity4 chemotherapy prevents improves the prognosis of @entity0 with @entity1 after D2 gastrectomy.

title: Prolonged adjuvant XXXX chemotherapy improved survival of @entity1 after D2 gastrectomy.

answer: @entity4


abstract: GOALS: This study aims to investigate the safety and efficacy of prolonged adjuvant @entity4 chemotherapy on survival of @entity3 after D2 gastrectomy. BACKGROUND: Inadequate evidence is available on optimal duration of chemotherapy and the number of administered cycles is generally based on @entity0 responsiveness and individual tolerability as well as physician preferences. STUDY: We randomly assigned 307 @entity3 @entity0 after D2 gastrectomy between January 2006 and December 2010 to XELOX group and Prolonged group. XELOX consisted of a 2-h intravenous infusion of @entity5 130mg/mg on day 1 and oral @entity4 1000mg/m(2) twice daily on days 1-14 of a 3-week cycle for eight cycles in half a year. In Prolonged group, @entity0 underwent extra oral @entity4 1000mg/m(2) twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX. The disease-free survival and overall survival were compared. RESULTS: Significant differences were found in 3-year disease-free survival (Prolonged group 56.6%, XELOX group 48.4%, P=0.0357). Subgroup analysis by TNM staging showed that @entity0 with @entity1 in the Prolonged group had significantly higher DFS (50.00% vs 40.96, P=0.0178) and @entity6 (71.95% vs 57.83, P=0.0230) than that of @entity0 in the XELOX group. No grade 4 adverse effects or treatment-related @entity2 were reported. More @entity0 in the Prolonged group experienced @entity7 than in the XELOX group. CONCLUSIONS: Prolonged @entity4 chemotherapy prevents improves the prognosis of @entity0 with @entity1 after D2 gastrectomy.

title: Prolonged adjuvant @entity4 chemotherapy improved survival of XXXX after D2 gastrectomy.

answer: @entity1


abstract: A psychrotolerant bacterial strain of @entity2 , originally isolated from a glacial site in Indian Himalayan Region (IHR), has been investigated for laccase production under different culture conditions. The bacterial strain was found to grow between 4 to 45  C (opt. 25  C) and 3 to 14 pH (opt. 5 pH) on prescribed growth medium, coinciding with production of laccase in laccase producing medium. However, the production of laccase was more consistent toward alkaline pH. Laccase enzyme was partially purified using gel filtration chromatography. The molecular mass of laccase was determined ~53  kDa on native PAGE. The Km and Vmax values were determined to be 0.10  mM and 50.00   M  min(-1), respectively, with @entity3 . Inoculum size (4.0% v/v at 1.5 O.D.) resulted in significantly higher production of laccase. @entity0 and @entity1 sources also affected the laccase production significantly. All the @entity0 sources enhanced laccase production, xylose being the best enhancer (P   <   0.01). Among @entity1 sources, organic sources were found to act as inhibitors (P   <   0.01), and among the in-organic sources only @entity4 enhanced the laccase production. Low molecular weight organic solvents significantly (P   <   0.01) enhanced laccase production up to 24  h of incubation with a decline in later incubation period. Production of laccase by the psychrotolerant bacterium in wide range of temperature and pH is likely to have inference in biotechnological processes.

title: A psychrotolerant strain of XXXX (MTCC 4822) produces laccase at wide temperature and pH range.

answer: @entity2


abstract: The present study was aimed at investigating the prevalence of @entity2 in the elderly, aged 65 years or older, in a community of southern Taiwan. By using the records of the local household registry, a sampling frame for the elderly population was constructed, and a sample of 1,400 subjects was drawn by simple random sampling. After the exclusion of nonresponse subjects, 917 subjects aged between 65 and 88 years (mean 71.9) were included in our survey. The serum thyrotropin levels of these @entity0 were measured by monoclonal antibodies TSH immunoradiometric assays. A normal range, 0.45-4.65 microU/ml, was determined from the middle 95% of the TSH distribution of 140 'disease-free' subjects. By reference to the normal range, 23 (2.51%) @entity0 had high (> 4.65 microU/ml), and 41 (4.47%) had low (< 0.46 microU/ml) TSH levels. The overall prevalence of @entity2 in the sample was 6.98%. Of the 23 @entity0 with high TSH levels, 8 (34.8%) had low free T4 values (< 1.21 ng/dl), so-called @entity3 , and of the 41 @entity0 with low TSH levels, only 1 (2.4%) had high T3 values, so-called T3 @entity5 . Antithyroid antibodies were found in 56.5% of those with high TSH levels but only 12.2% of those with low TSH levels (odds ratio = 8.53, 95% confidence limits = 2.55-28.50, p < 0.001). This result indicates that @entity1 is still the major cause of @entity3 in aged @entity0 . However, the prevalence of subclinical @entity4 is higher than that of @entity3 and it might relate to nonautoimmune factors.

title: Prevalence study of XXXX in the elderly of Taiwan.

answer: @entity2


abstract: @entity10 is an uncommon but life-threatening condition whose management is still debated. The rarity of this disease explains the lack of a standard management. Between 1986 and 1996, eight @entity0 younger than 1 year were referred to our Institution with a @entity9 . The median age at operation was 3.15 months and the median weight was 4.5 kg. The diagnosis was made after an episode of @entity7 in all but one and was confirmed by fiberoptic bronchoscopy. The median length of @entity9 was 24.5 mm (Ranges: 4-30 mm). Only one @entity0 was free from associated @entity1 . Tracheal repair was performed under cardiopulmonary bypass in all. In three it was achieved by pericardial augmentation of the stenosed area, in four by resection and end to end @entity4 and in one by sliding tracheoplasty. Concomitant cardiac repair was performed in six. Two @entity0 died after pericardial patch augmentation. In both, @entity3 was related to profound @entity6 due to patch collapse. Two @entity0 developed @entity5 after resection and end to end @entity4 . They both had stent placement and one required reoperation and underwent a sliding tracheoplasty. At a median follow-up of 21 months (Ranges: 6-120) all the survivors are doing well and are free from respiratory symptoms. Bronchoscopic evaluation revealed in all a widely patent @entity4 without @entity5 . In conclusion, @entity9 in @entity0 remains a @entity2 . Surgical technique, whether resection and end to end @entity4 or sliding tracheoplasty offer better results and should be discussed according to the length of the @entity8 . Pericardial plasty should be used with caution.

title: Tracheoplasty in XXXX .

answer: @entity10


abstract: BACKGROUND: Differentiation between acute cortical and subcortical @entity5 may be problematic when cortical @entity3 presents without obvious @entity2 such as @entity11 , neglect or @entity10 . This study explores @entity3 risk factors and clinical variables that may assist in this differentiation. METHODS: Records of consecutive @entity0 with acute @entity5 , examined within 72 h of symptom onset, were reviewed. @entity3 type was verified by clinical course and follow-up imaging. @entity3 risk factors and acute examination findings were compared by odds ratios and positive predictive values for cortical and subcortical @entity3 . RESULTS: For 355 @entity0 studied, 237 had cortical @entity3 and 118 had subcortical @entity3 . Odds ratios for cortical @entity3 were highest for @entity8 by EKG (OR = 4.77, CI = 2.08-10.94), recent hospitalization (OR = 4.51, CI = 2.39-8.53) and nonalert mental status (OR = 4.50, CI = 2.29-8.87). Possible @entity6 , @entity7 and @entity9 were also significant, but @entity4 , age and @entity1 were not significantly different for the @entity3 subtypes. @entity2 were absent in 19.4% of cortical @entity3 @entity0 on initial examination. Predictive models were generated based on the presence or absence of @entity2 and the interaction of significant risk factors with degree of @entity2 . CONCLUSIONS: There are clinical features that, in addition to initial examination, may help differentiate cortical from subcortical @entity5 . These features may be relevant to both diagnostic and therapeutic approaches to @entity3 .

title: Differentiation of acute cortical and subcortical XXXX by risk factors and clinical examination findings.

answer: @entity5


abstract: BACKGROUND: @entity4 repair (LVHR) is a common procedure in abdominal surgery. Use of mesh has become the gold standard in the last decade because of significantly fewer recurrences. Subsequently, the attention shifted to reduce mesh related complications in the short- and long-term as well as to facilitate its handling and positioning. In continuation of our previous study, we conducted a final analysis about the use of the Ventralight    ST @entity3 patch (Davol Inc, Subsidary of C. R. Bard, Inc. Warwick, RI). METHODS: Prospectively collected data of 61 consecutive @entity0 ( @entity0 / @entity0 : 44/17) from July 2011 to October 2013 were analysed in this final study. @entity0 were evaluated clinically at four time points in total. At the final clinical check- up, 97% of the total study population was reassessed. The primary outcome parameter was recurrence. Secondary outcome parameters were described in terms of mesh related complications, @entity2 scores, and quality of life. RESULTS: Mean follow-up time was 23 months (range 16-44). Mean length of hospital stay was four days (range 2-17). There were no operative complications. Two @entity0 (both > 80 years old) died more than one year after the procedure because of a cardiovascular event. One morbidly @entity1 @entity0 (2%) treated for a recurrent incisional @entity3 showed a second recurrence at the last follow-up visit. A clinical significant seroma was observed in two @entity0 (3%) one month postoperatively. At last follow-up, two @entity0 (3%) reported persistent mild discomfort at one specific spot. There was a significant reduction in the visual analogue scale (VAS) scores at the last follow-up visit compared to preoperative scores (3.01 vs. 0.27; P < 0.01). Quality of life measurements using the SF-36 questionnaire showed good results. CONCLUSION: This final analysis of long-term follow-up results on the use of the Ventralight    ST @entity3 patch in laparoscopic @entity4 repair confirms our preliminary findings of the previous two reports. Use of the Ventralight    ST @entity3 patch is associated with good short- and long-term outcomes and can be considered as safe and feasible in LVHR.

title: Long-term Outcome on the use of the Ventralight    ST Hernia Patch in XXXX .

answer: @entity4


abstract: Hemostasis is extremely important in neurosurgical procedures to prevent major postoperative bleedings and their catastrophic consequences. Emoxicel @entity3 Retilight (Bioster, a.s., Czech Republic) is a sterile, resorbable, hemostatic reticulum, mainly used to stop capillary and @entity1 . The textile form of the hemostatic material allows, in several cases, perfect adjustment to the varied shape of the surgical cavities and of the epidural space to which it adheres when wet. @entity2 effect is rapid, and complete hemostasis can be achieved in several minutes after application. This topical hemostatic agent is biocompatible, biodegradable, and highly resorbable. It has a hemostatic and antimicrobic effect. The main aim of this study was to verify the efficacy, broadness of use, and safety of this topical hemostatic in neurosurgical procedures. A total of 43 cases were included, 18 cranial and 25 spinal, and in only one case a postoperative epidural @entity1 was reported. A histopathologic study of the hemostatic was performed. No @entity0 were reported. Emoxicel was useful not only in stopping minor @entity1 , but also for @entity1 prevention in the postoperative period.

title: A Clinico-pathologic Study of Oxidized Cellulose as Topical XXXX Agent in Neurosurgery.

answer: @entity2


abstract: UNASSIGNED: @entity4 is one of the most common causes of disability and @entity2 in @entity0 younger than one year of age. The syndrome is the result of major mechanical forces affecting the head and central nervous system. The outcome for surviving @entity0 is often poor, with both physical and mental disabilities. @entity7 has been reported as a finding after such shaking. The present case involves a one-month-old @entity0 who was brought to hospital by his father because of somnolence and feeding aversion. Radiological imaging revealed subdural haematomas, and fundoscopy found @entity5 . During police interrogation, the father confessed to having shaken the @entity0 . Cranial ultrasonography subsequently showed increasing damage of the brain; the @entity0 's general condition worsened. Eight weeks after admission, he died due to @entity1 . Upon autopsy, the brain was @entity3 , with massive @entity6 . The case presented impressively shows the possible serious outcome of an admitted incident of shaking and emphasises the importance of an accurate education of parents about its severe and possible lethal consequences.

title: Long-term outcome in a case of XXXX .

answer: @entity4